BMS submits daclatasvir, asunaprevir NDAs

Bristol-Myers Squibb Co. (NYSE:BMY) submitted a pair of NDAs to FDA for daclatasvir ( BMS-790052) and asunaprevir ( BMS-650032) to treat HCV genotype Ib infection. The NDAs support the use of the compounds in combination, for which BMS has breakthrough therapy designation from FDA. BMS said the NDA for daclatasvir also covers its use in combination with other agents for multiple HCV genotypes. ...